Clinical trial • Phase II | Phase IV • Psychiatry

Estradiol for Postpartum depression | Perinatal depression

Phase II | Phase IV trial of Estradiol for Postpartum depression | Perinatal depression. Placebo (Comfeel Plus Transparent from Coloplast).-controlled.

Overview

Trial Therapeutic Area
Psychiatry
Trial Disease
Postpartum depression | Perinatal depression
Trial Stage
Phase II | Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
26-09-2024
First CTIS Authorization Date
08-10-2024

Trial design

Placebo (Comfeel Plus Transparent from Coloplast).-controlled Phase II | Phase IV trial across 4 sites in Denmark.

Comparator
Placebo (Comfeel Plus Transparent from Coloplast).
Target Sample Size
220
Trial Duration For Participant
180

Eligibility

Recruits 220 Vulnerable population flag selected. Trial population consists of pregnant/postpartum adult women (aged 18-45). No detailed consent/assent handling information is provided in the available source documents..

Pregnancy Exclusion
Pregnancy-related hypertension or preeclampsia.
Vulnerable Population
Vulnerable population flag selected. Trial population consists of pregnant/postpartum adult women (aged 18-45). No detailed consent/assent handling information is provided in the available source documents.

Inclusion criteria

  • {"criterion_text":"- Women between 18 and 45 years and pregnant in the third trimester."}
  • {"criterion_text":"- Previously perinatal depression with the onset of depressive episode in pregnancy or within 6 months of birth or untreated depressive episode assessed by retrospective interview by healthcare professional."}

Exclusion criteria

  • {"criterion_text":"- Antidepressant treatment by inclusion in the study."}
  • {"criterion_text":"- Pregnancy-related hypertension or preeclampsia."}
  • {"criterion_text":"- Manifest atherosclerosis or known cardiovascular risk factors (including diabetes, hypertension)."}
  • {"criterion_text":"- Other contraindication for estrogen treatment (e.g. acute liver disease, varicicated varicencies)."}
  • {"criterion_text":"- Use of psychotropic pharmacology, except for short-term sleep support treatment, which is likely to influence the results of the study."}
  • {"criterion_text":"- Non-fluent in Danish or pronounced vision or hearing loss."}
  • {"criterion_text":"- Current or previous learning difficulties."}
  • {"criterion_text":"- BMI >35 kg/m2."}
  • {"criterion_text":"- Current alcohol or drug abuse."}
  • {"criterion_text":"- Multiple pregnancy."}
  • {"criterion_text":"- Severe postpartum haemorrhage (>1500 ml)."}
  • {"criterion_text":"- Moderate to severe depression developed in pregnancy before day 0 postpartum."}
  • {"criterion_text":"- Serious illness or neonatal death in the child."}
  • {"criterion_text":"- Severe mental illness, e.g. diseases of the schizophrenic spectrum, psychotic conditions, inpatient active eating disorder or hospitalising OCD, and bipolar affective disorder."}
  • {"criterion_text":"- Previous suicide attempts outside the depressive episode."}
  • {"criterion_text":"- Present or previous neurological disease including migraines and epilepsy."}
  • {"criterion_text":"- Severe medical disease."}
  • {"criterion_text":"- Past or ongoing cancer."}
  • {"criterion_text":"- Previous venous thromboembolism, myocardial infarction, cerebrovascular thromboembolism or known thrombophilic diseases and risk factors clinically assessed after thrombophilic screening."}
  • {"criterion_text":"- Deep vein thrombosis or pulmonary embolism in current pregnancy."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Clinical depression according to DSM-V criteria. Between 2 weeks and 6 months postpartum","definition_or_measurement_approach":"Clinical diagnosis according to DSM-V criteria between 2 weeks and 6 months postpartum."}

Recruitment

Planned Sample Size
220
Recruitment Window Months
75
Consent Approach
Informed consent documents are listed (L2_ICF and L1_SIS) but their contents are not available in the provided source. Consent is from the adult participant (women aged 18-45). No details on assent, age-specific documents or languages available are provided in the source.

Geography

Total Number Of Sites
4
Total Number Of Participants
220

Denmark

Earliest CTIS Part Ii Submission Date
11-09-2024
Latest Decision Or Authorization Date
08-10-2024
Processing Time Days
27
Number Of Sites
4
Number Of Participants
220

Sites

Site Name
Hvidovre Hospital
Department Name
Department of Obstetric and gynecology
Contact Person Name
Anette Kjaerbye-Thygesen
Site Name
Nordsjaellands Hospital
Department Name
Gynaekologisk-obstetrisk afdeling 0111
Contact Person Name
Ellen Loekkegaard
Site Name
Rigshospitalet
Department Name
Obstetrisk Afdeling
Contact Person Name
Kristina Martha Renault
Site Name
Copenhagen University Hospital
Department Name
Afdeling for kvindesygdomme, graviditet og fødsler
Contact Person Name
Eleonora Cvetanovska

Sponsor

Primary sponsor

Full Name
Rigshospitalet
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"sponsorDuties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
Vivelle Dot 100 mikrogram/24 timer, depotplaster.
Active Substance
Estradiol
Modality
Small molecule
Routes Of Administration
TRANSDERMAL USE
Route
Transdermal
Authorisation Status
Marketing authorisation present (MA number 32855)
Starting Dose
100 µg/24 hours
Frequency
Every 24 hours
Maximum Dose
200 µg microgram(s)
Investigational Product Name
Placebo is Comfeel Plus Transparent from Coloplast. The Comfeel Plus Transparent is a thin and flexible hydrocolloid dressing. https://www.coloplast.dk/comfeel-plus-transparent-da-dk.aspx#section=product-description_3
Modality
Other

Related trials

Other published trials that may interest you.